What can be said about MOTS-c side effects from human evidence? A complete list or frequency estimate is not established by the available human sources reviewed here. One human study measured the body's own MOTS-c after exercise; a separate phase 2a trial registry now lists administered MOTS-c, but has no posted results. The completed human trial often discussed alongside MOTS-c studied CB4211, an analog, not MOTS-c itself.
Three different kinds of human evidence
| Source | What was studied | What it says about side effects | Limit |
|---|---|---|---|
| Reynolds and colleagues, 2021 | Exercise-related measurements of endogenous MOTS-c in ten young men; administered-peptide experiments were in mice. | The human arm did not administer MOTS-c, so it cannot estimate reactions to an injection. | Physiology measurements are not a treatment safety study. |
| CB4211 study NCT03998514 and CohBar's 2021 topline report | Phase 1a/1b program for CB4211, a MOTS-c analog. The company reported a four-week, 25 mg daily subcutaneous Phase 1b portion in 20 participants. | The company reported no serious adverse events; transient, generally mild-to-moderate injection-site reactions occurred in more than 10% of CB4211 recipients in Phase 1b. | This is sponsor-reported topline data for an analog and a small, short study. It does not establish a MOTS-c side-effect rate. |
| MOTS-MET study NCT07505745 | Registry lists a randomized, placebo-controlled phase 2a trial of MOTS-c itself, estimated enrollment 120, once-daily subcutaneous treatment for 12 weeks, with safety follow-up through week 16. | The registry lists safety outcomes, but its record has no posted results section. | A registered study design is not an observed adverse-event result. The public record does not state the fixed dose. |
What the side-effect evidence does and does not show
The CB4211 report provides a limited, compound-specific observation: injection-site reactions were the only events reported above 10% among CB4211 recipients during the four-week Phase 1b portion. It does not show that native MOTS-c has the same profile. For MOTS-c itself, the registry describes a study designed to collect safety information, but no outcomes are posted in the record. The human exercise study concerns endogenous MOTS-c, not an administered product.
For a reported reaction to support a frequency claim, the source needs to identify the exact intervention, exposed participant count, comparison group, event definition and observation period. Anecdotal lists without those details cannot show which events are common or rare. This distinction matters especially when an article combines a native peptide, an analog, animal findings and online reports.
FAQ
Are injection-site reactions a known common side effect of MOTS-c?
The sponsor reported injection-site reactions in more than 10% of CB4211 recipients in one small four-week study. CB4211 is an analog. The registered trial of MOTS-c itself has no results posted, so that percentage cannot be presented as a MOTS-c rate.
From the FormBlends catalog
MOTS-c
Mitochondrial-derived exercise mimetic that regulates metabolic homeostasis · From $249/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View MOTS-c →Does the human exercise study provide a side-effect list?
No. It measured naturally occurring MOTS-c around exercise. It did not administer MOTS-c to the human participants.
Has a study of MOTS-c itself collected human safety outcomes?
ClinicalTrials.gov lists NCT07505745, a phase 2a trial of MOTS-c itself. The registry record lists a safety follow-up period but currently contains no posted results. Study plans do not reveal which adverse events occurred.
Why is CB4211 discussed separately?
The registry and sponsor report identify CB4211 as a MOTS-c analog. Keeping that molecule separate avoids transferring its results to a different intervention.
The pre-existing theoretical-concern and precaution sections below are retained page content, not event rates measured in these studies. The available sources reviewed here do not establish the frequency of the listed conditions or validate a complete MOTS-c side-effect checklist.
Rare and Theoretical Concerns
These are concerns that either have very limited reports or are theoretical based on MOTS-c's mechanism of action:
- Allergic reactions: As with any injectable substance, allergic reactions are theoretically possible, though none have been widely reported with MOTS-c
- Interaction with cancer biology: MOTS-c influences AMPK and metabolic pathways involved in cell growth. While preclinical data has actually shown anti-tumor properties, individuals with active cancer shouldn't use MOTS-c without oncologist approval
- Hormonal interactions: MOTS-c's metabolic effects could theoretically influence hormone levels, though no significant hormonal disruptions have been documented in available research
Who Should Avoid MOTS-c
- Pregnant or breastfeeding women (no safety data available)
- Individuals with active cancer (discuss with oncologist first)
- People with Type 1 diabetes (risk of hypoglycemia without careful monitoring)
- Anyone with a known allergy to peptide compounds
- Individuals under 18 years of age
Monitor your glucose closely if you take diabetes medications and discuss MOTS-c with your prescribing physician.
Monitor your blood sugar closely and inform your physician about all medications you take.
Ready when you are
MOTS-c
Mitochondrial-derived exercise mimetic that regulates metabolic homeostasis · From $249/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View MOTS-c →